Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics, trading under ASX:TYP, is focusing on the development of psilocybin-based treatments, which are currently under regulatory review. The company emphasizes that its products will only be commercialized following approvals that confirm their safety and efficacy. Investors should note that psilocybin remains a controlled substance and its use is strictly regulated.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.